SIA
REGN icon

Schear Investment Advisers’s Regeneron Pharmaceuticals REGN Stock Holding History

Schear Investment Advisers’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-288
Closed -$205K – 91
2024
Q4 		$205K Sell
288
-90
-24% -$75.5K 0.11% 86
2024
Q3 		$397K Buy
+378
New +$421K 0.25% 77

Other funds holding REGN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Schear Investment Advisers's REGN Position: Q1 2025 in Review

Schear Investment Advisers sold out of Regeneron Pharmaceuticals (REGN) in Q1 2025, closing a stake of 288 shares — an estimated $205K sold.

Schear Investment Advisers first reported a position in REGN in Q3 2024 and held it in 2 quarters. The position peaked at $397K in Q3 2024. 1,290 funds tracked by Wall St. Rank hold REGN as of Q1 2025.

  • Schear Investment Advisers reported no remaining Regeneron Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Schear Investment Advisers sold 288 Regeneron Pharmaceuticals shares in Q1 2025, an estimated $205K.
  • Schear Investment Advisers first reported a position in Regeneron Pharmaceuticals in Q3 2024 and held it in 2 quarters.
  • Schear Investment Advisers's Regeneron Pharmaceuticals position peaked at $397K in Q3 2024.
  • 1,290 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2025.

Based on Schear Investment Advisers's 13F filing for Q1 2025, filed 1 May 2025.